Your session is about to expire
← Back to Search
IMR-687 for Sickle Cell Disease
Study Summary
This trial will evaluate the long-term safety and tolerability of IMR-687 in adult patients who have completed a previous study on the same drug.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 2 trial • 100 Patients • NCT03401112Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not pregnant, not breastfeeding, and unlikely to get pregnant.I am a male and unlikely to father a child.I understand the study and can sign the consent form.I do not have active hepatitis B or C, malaria, or HIV.
- Group 1: Open Label
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there similar treatments to IMR-687 that have been trialed before?
"At this moment in time, there is exactly one clinical trial researching IMR-687. Additionally, none of the live studies are in Phase 3 of testing. Most trials for IMR-687 originate from London or Connecticut; however, there are 7 total locations running these tests."
What are the potential risks associated with taking IMR-687?
"Although there is data suggesting IMR-687 is safe, it only received a 2 because there are no studies proving its efficacy."
How many people are being studied in this clinical trial at present?
"Unfortunately, this research is not presently enrolling new participants. The trial was originally posted on May 22nd, 2019 and updated as recently as March 2nd, 2022. However, if you are seeking other studies, there are 202 trials actively recruiting patients with anemia and sickle cell disease; in addition, there is 1 study for IMR-687 that is also looking for new patients."
What are the origins of this trial?
"IMR-687 has been researched since 2019 with the first study being completed that same year. 30 participants were involved in this initial Imara, Inc.-sponsored trial. After Phase 2 clinical approval was received in 2019, there is now a single active trial for IMR-687 again sponsored by Imara, Inc.."
Is this a full clinical trial or are there still available positions for patients?
"As of right now, this clinical trial is not admitting any more patients. The study was originally posted on May 22nd, 2019 but was edited most recently on March 2nd, 2022. If you're looking for other trials, there are 202 studies for anemia, sickle cell and 1 study for IMR-687 that are still active."
Share this study with friends
Copy Link
Messenger